The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Sale of assets | 0 | 0 |
| Net cash provided by(used in) investing activities | 0 | 0 |
| Reverse stock split rounding adjustment | 0 | - |
| Loss on sale of assets | 0 | 0 |
| Amortization of discount on preferred stock | 0 | 0 |
| Other liabilities-Nonrelated Party | - | -212,316 |
| Inventory | 0 | 0 |
| Other liabilities-Related Party | - | 9,175 |
| Accrued liabilities - related parties | -30,000 | 30,000 |
| Net loss | -7,618,776 | -10,255,309 |
| Depreciation | 255 | 502 |
| Issuance of common stock for services | 5,543,101 | 5,113,591 |
| Loss on debt settlement | -125,625 | - |
| Options vested for stock-based compensation | 1,099,793 | 101,958 |
| Operating lease right of use asset | 16,459 | 31,823 |
| Amortization of license agreement | -260,186 | 695,811 |
| Amortization on intangible assets | 284,759 | 554,913 |
| Prepaid expenses | 100,000 | 0 |
| Accounts payable and accrued liabilities | -276,656 | 430,494 |
| Operating lease right of use liabilities | -17,950 | -34,845 |
| Payroll tax liabilities | 1,487 | 2,973 |
| Other liabilities | -212,316 | - |
| Net cash used in operating activities | -1,241,264 | -3,531,230 |
| Proceeds from borrowings on notes payable | 0 | 500,000 |
| Proceeds from borrowings on notes payable - related parties | 0 | 100,000 |
| Proceeds from sales of common stock | 1,324,571 | 1,085,785 |
| Proceeds from sales of series b convertible preferred stock | 0 | 100,000 |
| Proceeds from exercise of warrants | 297,000 | 630,000 |
| Proceeds from exercise of warrants | - | 1,150,000 |
| Collection of subscriptions receivable | 1,150,000 | - |
| Net cash provided by financing activities | 1,621,571 | 3,565,785 |
| End of period | 380,307 | 34,555 |
| Cash and cash equivalents at beginning of period | 101,019 | 58,653 |
| Effect of exchange rate changes on cash | -45 | 7,811 |
| Cash and cash equivalents at end of period | 481,281 | 101,019 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)